Therasense Competitors

Pink Sheets . USA . 
Stock . Therasense
THER Stock  USD 0.0001  0.00  0.00%   
Therasense competes with Scisparc, Creative Medical, Sonnet Biotherapeutics, Inhibikase Therapeutics, and Tempest Therapeutics; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing Therasense competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Therasense to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Therasense Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Therasense competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Therasense's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.00010.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.0000840.00
Details

Therasense Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Therasense and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Therasense and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Therasense does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
IKT
+ 0.7
ENZC
ENZC
+ 0.63
GBLX
IKT
+ 0.48
GBLX
RGBP
+ 0.41
GBLX
SPRC
+ 0.29
GBLX
RGBP
+ 0.27
SPRC
  
High negative correlations   
ENZC
- 0.65
CELZ
CELZ
- 0.51
GBLX
IKT
- 0.5
CELZ
SONN
- 0.32
CELZ
CELZ
- 0.25
SPRC
RGBP
- 0.22
CELZ

Risk-Adjusted Indicators

There is a big difference between Therasense Pink Sheet performing well and Therasense Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Therasense's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
GLSH  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
ATRX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
GBLX  21.92  4.52  0.21 (0.48) 20.60 
(43.17)
 33.33 
(22.22)
 488.00 
SPRC  11.15  2.80  0.26  0.82  7.61 
(20.90)
 25.00 
(14.00)
 150.68 
CELZ  6.19  0.79  0.11  3.12  8.04 
(6.95)
 18.61 
(9.85)
 56.11 
RGBP  12.35  1.09  0.04  0.07  12.74 
(17.50)
 25.76 
(23.82)
 96.95 
ENZC  5.85 (0.37) 0.00 (0.46) 0.00 
 0.00 
 14.29 
(14.29)
 44.44 
SONN  3.85 (0.12) 0.00 (0.34) 0.00 
 0.00 
 9.38 
(7.33)
 44.37 
IKT  5.02 (0.76) 0.00  0.32  0.00 
 0.00 
 11.20 
(13.42)
 42.63 
SIOX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
All Fundamental Data

Therasense Competitive Analysis

The better you understand Therasense competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Therasense's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Therasense's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
THER GBLX SPRC CELZ RGBP ENZC SONN IKT TPST LEXX
 0.00 
 0.0001 
Therasense
 14.29 
 0.0008 
GBLX
 2.78 
 0.35 
Scisparc
 14.77 
 3.00 
Creative
 23.90 
 0.06 
Regen
 12.50 
 0.0007 
Enzolytics
 5.04 
 1.32 
Sonnet
 1.35 
 2.20 
Inhibikase
 2.47 
 0.83 
Tempest
 8.33 
 1.32 
Lexaria
Market Volatility
(90 Days Market Risk)
Very steady
Out of control
Out of control
Relatively risky
Out of control
Out of control
Not too volatile
Very risky
Relatively risky
Risky
Market Performance
(90 Days Performance)
Very Weak
OK
OK
OK
Weak
Very Weak
Very Weak
Very Weak
Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Very High
High
Low
Average
Very High
Quite High
Very High
Average
Very High
Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Strong Buy
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Cautious Hold
Sell
Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Cautious Hold
Current Ratio
0.22
0.03
5.59
58.88
0.05
0.01
1.1
7.56
3.05
40.09
Net Asset
N/A
2.55 M
11.18 M
10.72 M
559 K
3.31 M
2.77 M
14.51 M
51.6 M
8.87 M
Profit Margin
N/A
N/A
N/A
N/A
6.09
N/A
N/A
N/A
N/A
N/A
EBITDA
(5.53 M)
398.73 K
(5.31 M)
(5.53 M)
2.44 M
(886.77 K)
(11.85 M)
(19.91 M)
(28.78 M)
(5.68 M)
Current Valuation
27.3 M
10.19 M
1.4 M
(116.71 K)
22.4 M
71.57 M
(703.82 K)
146.81 M
30.82 M
17.29 M
Price To Book
0.86
1.08
0.56
0.94
N/A
N/A
1.0
26.46
3.07
2.59
Operating Margin
N/A
N/A
-4.2
-511.82
-2.96
-19.24
-2.85
N/A
N/A
-14.63
Retained Earnings
(248.68 M)
(78.28 M)
(68.69 M)
(59.1 M)
(17.78 M)
N/A
(117.68 M)
(66.9 M)
(165.26 M)
(51.56 M)
Current Asset
18.12 M
2.2 M
N/A
N/A
171 K
N/A
N/A
N/A
N/A
N/A
Beta
22.12
0.56
0.8
4.6
3.36
-0.0481
1.01
1.05
-2.57
0.96
Number Of Employees
16
3
3
4
1
7
13
8
17
7
Shares Outstanding
6.15 B
379.21 M
10.83 M
1.75 M
5.05 B
2.44 B
3.07 M
72.68 M
43.64 M
17.55 M
Cash Flow From Operations
(5.54 M)
(1.87 M)
(5.89 M)
(8.03 M)
(606.92 K)
4.89 M
(8.61 M)
(18.09 M)
(27.36 M)
(4.96 M)
Total Debt
2.9 M
397.31 K
76 K
14.19 K
1.58 M
233.12 K
130.86 K
622 K
20.66 M
137.37 K
Return On Equity
N/A
-50.98
-0.86
-0.57
N/A
N/A
-2.85
-2.7
-6.92
-1.15
Z Score
-1.4
-30.0
N/A
N/A
-26.6
N/A
N/A
N/A
N/A
N/A
Return On Asset
-169.9
-0.21
-0.39
-0.36
-0.76
-7.05
-1.34
-1.13
-0.77
-0.67
Number Of Shares Shorted
199.92 K
N/A
65.18 K
98.25 K
N/A
N/A
79.67 K
1.26 M
2.11 M
539.37 K
Book Value Per Share
N/A
-0.004
1.93
4.93
-0.001
-0.63
1.34
-0.071
0.43
0.56
Current Liabilities
11.29 M
1.32 M
N/A
N/A
649 K
N/A
N/A
N/A
N/A
N/A
Total Asset
52 M
2.55 M
11.18 M
10.72 M
559 K
3.31 M
2.77 M
14.51 M
51.6 M
8.87 M
Short Ratio
2.6
N/A
0.09
1.4
N/A
N/A
1.19
5.58
2.64
5.49
Debt To Equity
N/A
1.07
0.007
N/A
1.25
N/A
0.36
0.006
0.49
0.007
Target Price
N/A
N/A
N/A
30.0
N/A
N/A
160.0
8.0
18.75
7.5
Shares Owned By Institutions
N/A
N/A
1.22
1.71
N/A
N/A
3.05
76.01
15.53
8.12
Market Capitalization
20.3 M
8.21 M
3.85 M
6.14 M
10.1 M
125.65 M
4.05 M
162.08 M
35.47 M
25.28 M
Price To Earning
N/A
4.04
N/A
-54.81
N/A
N/A
N/A
N/A
0.23
N/A
Price To Sales
57.46
1.91
2.2
558.51
89.73
2083.26
4.05
1000000.0
N/A
50.86
Net Income
(7.75 M)
(530.87 K)
(5.12 M)
(5.29 M)
2.44 M
(57.28 K)
(7.44 M)
(19.03 M)
(29.49 M)
(5.81 M)
Earnings Per Share
-0.001
N/A
-5.28
-3.8
N/A
-4.76
-10.45
-3.12
-1.53
-0.5
Shares Owned By Insiders
83.61
13.08
N/A
2.01
0.06
N/A
1.58
12.34
0.16
7.8
Revenue
353.26 K
N/A
2.88 M
9 K
235.52 K
190 K
18.63 K
260.5 K
N/A
464.28 K
Working Capital
6.84 M
881 K
4.87 M
9.9 M
(478 K)
N/A
(1.09 M)
10.77 M
30.95 M
6.8 M
Cash And Equivalents
127.82 K
53.96 K
6.88 M
22.86 M
110.99 K
5.76 K
5.22 M
32.21 M
51.62 M
7.34 M
Cash Per Share
N/A
N/A
2.15
1.62
N/A
N/A
1.21
1.28
4.95
1.23
Gross Profit
256.68 K
(881.46 K)
1.21 M
6.6 K
235.52 K
52.81 K
(351.39 K)
(13.02 M)
N/A
494.2 K
Day Typical Price
1.0E-4
8.0E-4
0.36
3.16
0.0551
7.0E-4
1.36
2.18
0.85
1.35
Accumulation Distribution
N/A
0.13
0.18
0.19
N/A
0.13
0.0769
0.0796
0.0787
0.0638
Market Facilitation Index
N/A
1.0E-4
0.07
0.68
N/A
1.0E-4
0.11
0.18
0.07
0.09
Daily Balance Of Power
0.0
1.0
(0.14)
(0.76)
(9,223,372,036,855)
(1.00)
(0.64)
(0.17)
0.2857
(1.33)
Period Momentum Indicator
N/A
1.0E-4
(0.01)
(0.52)
(0.02)
(0.0001)
(0.07)
(0.03)
0.02
(0.12)
Rate Of Daily Change
1.0
1.14
0.97
0.85
0.76
0.88
0.95
0.99
1.02
0.92
Day Median Price
1.0E-4
8.0E-4
0.37
3.24
0.0551
8.0E-4
1.38
2.17
0.86
1.37
Price Action Indicator
N/A
1.0E-4
(0.02)
(0.50)
(0.01)
(0.0001)
(0.09)
0.015
(0.01)
(0.10)
Coefficient Of Variation
N/A
883.35
965.77
1161.43
4480.53
(1,696)
(3,166)
(1,466)
2851.06
(711.55)
Mean Deviation
N/A
21.92
11.15
6.19
12.35
5.85
3.85
5.02
2.88
4.0
Jensen Alpha
N/A
4.52
2.8
0.7903
1.09
(0.37)
(0.12)
(0.76)
0.3676
(0.47)
Total Risk Alpha
N/A
15.99
6.28
2.25
3.29
0.9584
0.8684
0.7492
0.8791
0.1306
Sortino Ratio
N/A
0.2079
0.2621
0.1051
0.0356
N/A
N/A
N/A
0.0642
N/A
Downside Variance
N/A
997.13
92.98
73.01
211.44
N/A
N/A
N/A
19.75
N/A
Standard Deviation
N/A
56.81
23.13
8.9
17.28
8.84
6.42
7.57
4.37
5.03
Kurtosis
N/A
39.72
19.37
2.52
2.67
0.4042
8.89
4.69
6.63
0.3799
Potential Upside
N/A
33.33
25.0
18.61
25.76
14.29
9.38
11.2
5.56
7.24
Treynor Ratio
N/A
(0.48)
0.8202
3.12
0.0749
(0.46)
(0.34)
0.3245
0.0908
(0.42)
Maximum Drawdown
N/A
488.0
150.68
56.11
96.95
44.44
44.37
42.63
26.61
22.45
Variance
N/A
3227.31
535.17
79.13
298.44
78.17
41.15
57.28
19.07
25.28
Market Risk Adjusted Performance
N/A
(0.47)
0.8302
3.13
0.0849
(0.45)
(0.33)
0.3345
0.1008
(0.41)
Risk Adjusted Performance
N/A
0.1054
0.097
0.0817
0.0284
(0.04)
(0.02)
(0.05)
0.0377
(0.11)
Skewness
N/A
5.64
4.14
0.144
1.12
0.1123
2.12
(0.82)
1.33
0.2475
Semi Deviation
N/A
20.6
7.61
8.04
12.74
N/A
N/A
N/A
3.47
N/A
Information Ratio
N/A
0.1155
0.1093
0.101
0.03
(0.04)
(0.01)
(0.05)
0.0654
(0.11)
Value At Risk
N/A
(22.22)
(14.00)
(9.85)
(23.82)
(14.29)
(7.33)
(13.42)
(5.95)
(8.33)
Expected Short fall
N/A
(43.17)
(20.90)
(6.95)
(17.50)
N/A
N/A
N/A
(3.69)
N/A
Downside Deviation
N/A
31.58
9.64
8.54
14.54
N/A
N/A
N/A
4.44
N/A
Semi Variance
N/A
424.35
57.84
64.66
162.25
N/A
N/A
N/A
12.04
N/A

Therasense Competition Performance Charts

Five steps to successful analysis of Therasense Competition

Therasense's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Therasense in relation to its competition. Therasense's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Therasense in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Therasense's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Therasense, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Therasense position

In addition to having Therasense in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Chemicals Thematic Idea Now

Chemicals
Chemicals Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Chemicals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Chemicals Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Therasense Pink Sheet Analysis

When running Therasense's price analysis, check to measure Therasense's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Therasense is operating at the current time. Most of Therasense's value examination focuses on studying past and present price action to predict the probability of Therasense's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Therasense's price. Additionally, you may evaluate how the addition of Therasense to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY